Sign In
Buy BDSX
Biodesix Earnings Calls
| Release date | May 04, 2026 |
| EPS estimate | -$1.26 |
| EPS actual | -$0.81 |
| EPS Surprise | 35.71% |
| Revenue estimate | 23.122M |
| Revenue actual | 25.555M |
| Revenue Surprise | 10.52% |
| Release date | Feb 26, 2026 |
| EPS estimate | -$1.05 |
| EPS actual | -$0.490 |
| EPS Surprise | 53.33% |
| Revenue estimate | 25.728M |
| Revenue actual | 28.755M |
| Revenue Surprise | 11.77% |
| Release date | Nov 03, 2025 |
| EPS estimate | -$1.60 |
| EPS actual | -$1.16 |
| EPS Surprise | 27.50% |
| Revenue estimate | 26.25M |
| Revenue actual | 21.768M |
| Revenue Surprise | -17.07% |
| Release date | Aug 07, 2025 |
| EPS estimate | -$1.40 |
| EPS actual | -$1.60 |
| EPS Surprise | -14.29% |
| Revenue estimate | 18.467M |
| Revenue actual | 20.018M |
| Revenue Surprise | 8.40% |
Last 4 Quarters for Biodesix
Below you can see how BDSX performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Aug 07, 2025 |
| Price on release | $0.447 |
| EPS estimate | -$1.40 |
| EPS actual | -$1.60 |
| EPS surprise | -14.29% |
| Date | Price |
|---|---|
| Aug 01, 2025 | $0.363 |
| Aug 04, 2025 | $0.384 |
| Aug 05, 2025 | $0.423 |
| Aug 06, 2025 | $0.390 |
| Aug 07, 2025 | $0.447 |
| Aug 08, 2025 | $0.401 |
| Aug 11, 2025 | $0.390 |
| Aug 12, 2025 | $0.411 |
| Aug 13, 2025 | $0.384 |
| 4 days before | 23.07% |
| 4 days after | -14.21% |
| On release day | -10.40% |
| Change in period | 5.59% |
| Release date | Nov 03, 2025 |
| Price on release | $6.27 |
| EPS estimate | -$1.60 |
| EPS actual | -$1.16 |
| EPS surprise | 27.50% |
| Date | Price |
|---|---|
| Oct 28, 2025 | $6.55 |
| Oct 29, 2025 | $6.54 |
| Oct 30, 2025 | $6.57 |
| Oct 31, 2025 | $6.83 |
| Nov 03, 2025 | $6.27 |
| Nov 04, 2025 | $7.60 |
| Nov 05, 2025 | $8.60 |
| Nov 06, 2025 | $7.79 |
| Nov 07, 2025 | $7.73 |
| 4 days before | -4.27% |
| 4 days after | 23.29% |
| On release day | 21.21% |
| Change in period | 18.02% |
| Release date | Feb 26, 2026 |
| Price on release | $14.22 |
| EPS estimate | -$1.05 |
| EPS actual | -$0.490 |
| EPS surprise | 53.33% |
| Date | Price |
|---|---|
| Feb 20, 2026 | $13.19 |
| Feb 23, 2026 | $12.77 |
| Feb 24, 2026 | $13.02 |
| Feb 25, 2026 | $12.93 |
| Feb 26, 2026 | $14.22 |
| Feb 27, 2026 | $15.33 |
| Mar 02, 2026 | $15.75 |
| Mar 03, 2026 | $15.50 |
| Mar 04, 2026 | $15.30 |
| 4 days before | 7.81% |
| 4 days after | 7.59% |
| On release day | 7.81% |
| Change in period | 16.00% |
| Release date | May 04, 2026 |
| Price on release | $11.27 |
| EPS estimate | -$1.26 |
| EPS actual | -$0.81 |
| EPS surprise | 35.71% |
| Date | Price |
|---|---|
| Apr 28, 2026 | $9.95 |
| Apr 29, 2026 | $9.84 |
| Apr 30, 2026 | $10.98 |
| May 01, 2026 | $11.08 |
| May 04, 2026 | $11.27 |
| May 05, 2026 | $14.94 |
| May 06, 2026 | $15.00 |
| May 07, 2026 | $15.47 |
| May 08, 2026 | $15.32 |
| 4 days before | 13.27% |
| 4 days after | 35.94% |
| On release day | 32.56% |
| Change in period | 53.97% |
Biodesix Earnings Call Transcript Summary of Q1 2026
Biodesix reported a strong start to 2026 with Q1 revenue of $25.6M, a 42% year-over-year increase driven by diagnostic testing (particularly Notify Lung) and a nearly doubled development services revenue. Test volumes grew 29% to ~17.8k tests, with primary care now representing ~15% of volumes. Gross margin expanded to 84% (82% ex a one-time tax recovery), improving ~300 bps year-over-year due to scale, better pricing realization, and lower cost per test. Operating expenses rose to support commercial expansion (about 100 sales reps planned to ramp at ~6 hires/quarter), while R&D increased modestly to support evidence generation. Net loss improved to $7.8M and adjusted EBITDA loss narrowed to $4.1M. Cash strengthened to $25.6M, aided by $16.8M of ATM proceeds. Management raised full-year 2026 revenue guidance to $108M–$114M (midpoint ~25% growth vs. 2025), attributing upside primarily to diagnostic testing volume growth, with development services expected to perform in line with prior expectations. Management emphasized continued focus on driving top-line growth, operational efficiency, commercial execution (including expanding primary care adoption), and advancing multi-omic pipeline and evidence generation to support long-term profitability.
